A detailed history of New York State Common Retirement Fund transactions in 89bio, Inc. stock. As of the latest transaction made, New York State Common Retirement Fund holds 13,167 shares of ETNB stock, worth $103,360. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,167
Previous 26,167 49.68%
Holding current value
$103,360
Previous $210,000 53.81%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$7.36 - $9.66 $95,680 - $125,580
-13,000 Reduced 49.68%
13,167 $97,000
Q2 2024

Jul 31, 2024

SELL
$7.31 - $10.9 $20,533 - $30,618
-2,809 Reduced 9.69%
26,167 $210,000
Q1 2024

May 07, 2024

BUY
$8.13 - $13.77 $23,861 - $40,414
2,935 Added 11.27%
28,976 $337,000
Q4 2023

Feb 01, 2024

BUY
$6.66 - $16.03 $7,925 - $19,075
1,190 Added 4.79%
26,041 $291,000
Q3 2023

Nov 07, 2023

BUY
$15.06 - $19.41 $9,804 - $12,635
651 Added 2.69%
24,851 $384,000
Q2 2023

Aug 07, 2023

BUY
$14.15 - $22.03 $342,430 - $533,126
24,200 New
24,200 $459,000
Q2 2022

Aug 04, 2022

SELL
$2.09 - $4.02 $16,929 - $32,561
-8,100 Reduced 98.95%
86 $0
Q1 2022

May 05, 2022

BUY
$3.45 - $14.99 $17 - $74
5 Added 0.06%
8,186 $31,000
Q4 2021

Feb 02, 2022

SELL
$11.15 - $19.66 $167 - $294
-15 Reduced 0.18%
8,181 $107,000
Q3 2021

Nov 02, 2021

BUY
$14.91 - $21.31 $447 - $639
30 Added 0.37%
8,196 $161,000
Q2 2021

Aug 02, 2021

BUY
$17.42 - $28.0 $1,149 - $1,848
66 Added 0.81%
8,166 $153,000
Q4 2020

Feb 08, 2021

BUY
$23.16 - $28.08 $97,272 - $117,936
4,200 Added 107.69%
8,100 $197,000
Q4 2019

Feb 05, 2020

BUY
$19.75 - $33.44 $77,025 - $130,415
3,900 New
3,900 $103,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $365M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.